share_log

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A：其他
美股SEC公告 ·  2024/06/08 04:03

Moomoo AI 已提取核心信息

Transcode Therapeutics, Inc. has filed an amendment to its definitive proxy statement with the SEC to correct an error regarding the quorum requirement for its upcoming Annual Meeting of Stockholders. The amendment clarifies that a quorum will require one-third of the outstanding shares entitled to vote, either present in person or represented by proxy. This correction aligns with the company's Amended and Restated Bylaws and the Delaware General Corporation Law. The Annual Meeting is scheduled for June 13, 2024, at Goodwin Procter LLP's offices in Boston, MA. The amendment does not change any other information in the original proxy statement, and stockholders who have already submitted their proxy cards or voting instructions do not need to take further action unless they decide to change their vote.
Transcode Therapeutics, Inc. has filed an amendment to its definitive proxy statement with the SEC to correct an error regarding the quorum requirement for its upcoming Annual Meeting of Stockholders. The amendment clarifies that a quorum will require one-third of the outstanding shares entitled to vote, either present in person or represented by proxy. This correction aligns with the company's Amended and Restated Bylaws and the Delaware General Corporation Law. The Annual Meeting is scheduled for June 13, 2024, at Goodwin Procter LLP's offices in Boston, MA. The amendment does not change any other information in the original proxy statement, and stockholders who have already submitted their proxy cards or voting instructions do not need to take further action unless they decide to change their vote.
Transcode Therapeutics公司已向美国证券交易委员会提交修正案，以更正有关即将举行的股东年会的法定代理人声明中有关法定人数要求的错误。该修正澄清了出席会议或通过委托书代表投票的未决表决权的三分之一构成法定人数的要求。这一更正符合公司的修订后章程和特拉华州公司法。年度股东会定于2024年6月13日在位于马萨诸塞州波士顿的Goodwin Procter LLP律师事务所举行。此修正版未更改原法定代理人声明中的任何其他信息，已提交其委托卡或投票指示的股东无需采取进一步行动，除非他们决定更改投票。
Transcode Therapeutics公司已向美国证券交易委员会提交修正案，以更正有关即将举行的股东年会的法定代理人声明中有关法定人数要求的错误。该修正澄清了出席会议或通过委托书代表投票的未决表决权的三分之一构成法定人数的要求。这一更正符合公司的修订后章程和特拉华州公司法。年度股东会定于2024年6月13日在位于马萨诸塞州波士顿的Goodwin Procter LLP律师事务所举行。此修正版未更改原法定代理人声明中的任何其他信息，已提交其委托卡或投票指示的股东无需采取进一步行动，除非他们决定更改投票。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股集体大涨！2025年中国资产前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 $阿里巴巴 (BABA.US)$ 、 $京东 (JD.US)$ 、 $富途控股 (FUTU.US)$ 等中概股价格飙升，市场情绪火热。 🎙️讨论： Deepseek 展开
    中国股票的疯狂反弹暂停？华尔街仍在大举押注热门股票